Despite disappointing results in a large sample of AD patients, insulin therapy merits further evaluation, with a reliable delivery strategy capable of penetrating the BBB, to alleviate cognitive and motor impairments in neurodegenerative disease. The gene discussed is INS; the disease is neurodegenerative disease.